641 related articles for article (PubMed ID: 30690295)
1. Treatment sequencing in metastatic colorectal cancer.
Modest DP; Pant S; Sartore-Bianchi A
Eur J Cancer; 2019 Mar; 109():70-83. PubMed ID: 30690295
[TBL] [Abstract][Full Text] [Related]
2. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.
Ciombor KK; Bekaii-Saab T
Oncologist; 2018 Jan; 23(1):25-34. PubMed ID: 29021377
[TBL] [Abstract][Full Text] [Related]
3. Options for Second-Line Treatment in Metastatic Colorectal Cancer.
Lee JJ; Sun W
Clin Adv Hematol Oncol; 2016 Jan; 14(1):46-54. PubMed ID: 27057668
[TBL] [Abstract][Full Text] [Related]
4. Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.
Bekaii-Saab T; Kim R; Kim TW; O'Connor JM; Strickler JH; Malka D; Sartore-Bianchi A; Bi F; Yamaguchi K; Yoshino T; Prager GW
Clin Colorectal Cancer; 2019 Mar; 18(1):e117-e129. PubMed ID: 30598357
[TBL] [Abstract][Full Text] [Related]
5. Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion.
Fernández-Montes A; Grávalos C; Pericay C; Safont MJ; Benavides M; Élez E; García-Alfonso P; García-Paredes B; Carrato A; Aranda E
Clin Colorectal Cancer; 2020 Sep; 19(3):165-177. PubMed ID: 32507561
[TBL] [Abstract][Full Text] [Related]
6. Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
Siebenhüner A; De Dosso S; Meisel A; Wagner AD; Borner M
Oncol Res Treat; 2020; 43(5):237-244. PubMed ID: 32146471
[TBL] [Abstract][Full Text] [Related]
7. Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR.
Sartore-Bianchi A; Siena S; Tonini G; Bardelli A; Santini D
Cancer Treat Rev; 2016 Dec; 51():54-62. PubMed ID: 27865140
[TBL] [Abstract][Full Text] [Related]
8. HER2-Positive Metastatic Colorectal Cancer.
Robinson HR; Messersmith WA; Lentz RW
Curr Treat Options Oncol; 2024 May; 25(5):585-604. PubMed ID: 38539034
[TBL] [Abstract][Full Text] [Related]
9. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
12. Current and advancing treatments for metastatic colorectal cancer.
Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
[TBL] [Abstract][Full Text] [Related]
13. Sequencing beyond the second-line setting in metastatic colorectal cancer.
Grothey A; Marshall JL; Bekaii-Saab T
Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):1-19. PubMed ID: 31730588
[TBL] [Abstract][Full Text] [Related]
14. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
[TBL] [Abstract][Full Text] [Related]
15. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
[TBL] [Abstract][Full Text] [Related]
16. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
Pohl M; Schmiegel W
Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
[TBL] [Abstract][Full Text] [Related]
18. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.
Giordano G; Parcesepe P; Bruno G; Piscazzi A; Lizzi V; Remo A; Pancione M; D'Andrea MR; De Santis E; Coppola L; Pietrafesa M; Fersini A; Ambrosi A; Landriscina M
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299337
[TBL] [Abstract][Full Text] [Related]
19. Current controversies in the management of metastatic colorectal cancer.
Vera R; Alonso V; Gállego J; González E; Guillén-Ponce C; Pericay C; Rivera F; Safont MJ; Valladares-Ayerbes M
Cancer Chemother Pharmacol; 2015 Oct; 76(4):659-77. PubMed ID: 26113053
[TBL] [Abstract][Full Text] [Related]
20. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.
Lee MS; Kopetz S
Clin Colorectal Cancer; 2015 Dec; 14(4):203-18. PubMed ID: 26077270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]